Skip to main content
. 2019 Jan 11;17(1):49. doi: 10.3390/md17010049

Figure 2.

Figure 2

Hypoglycemic effect of CYC27. (A) seven week measurement of fasting blood glucose (FBG) levels in BKS db mice after oral administration with vehicle, CYC27 and Rosiglitazone, and in BKS mice treated with vehicle. Data are expressed as mean ± SD (n = 8). ** p < 0.01, CYC27-50 group versus BKS db group. (B–E) show the blood glucose levels, GHb levels, GSA levels and insulin levels, respectively, at the seventh week. Data are shown as mean ± SD (n = 8). BKS group ## p < 0.01 and ### p < 0.01 versus BKS db group * p < 0.05, ** p < 0.01 and *** p < 0.001. BKS—vehicle-treated normal BKS mice; BKS db—vehicle-treated diabetic BKS db mice; Rosiglitazone—50 mg·kg−1·day−1 Rosiglitazone-treated BKS db mice; CYC27-50—50 mg·kg−1·day−1 CYC27-treated BKS db mice; CYC27-25—25 mg·kg−1·day−1 CYC27-treated BKS db mice.